Inozyme Pharma (NASDAQ:INZY – Get Free Report) and Theratechnologies (NASDAQ:THTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Volatility and Risk
Inozyme Pharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
Institutional and Insider Ownership
88.3% of Inozyme Pharma shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inozyme Pharma | 0 | 0 | 7 | 0 | 3.00 |
| Theratechnologies | 0 | 0 | 1 | 0 | 3.00 |
Inozyme Pharma presently has a consensus price target of $15.71, indicating a potential upside of 484.17%. Given Inozyme Pharma’s higher possible upside, research analysts plainly believe Inozyme Pharma is more favorable than Theratechnologies.
Profitability
This table compares Inozyme Pharma and Theratechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inozyme Pharma | N/A | -88.42% | -57.02% |
| Theratechnologies | -3.75% | N/A | -4.31% |
Earnings & Valuation
This table compares Inozyme Pharma and Theratechnologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inozyme Pharma | N/A | N/A | -$71.17 million | ($1.56) | -1.72 |
| Theratechnologies | $81.76 million | 0.68 | -$23.96 million | ($0.10) | -12.10 |
Theratechnologies has higher revenue and earnings than Inozyme Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Inozyme Pharma beats Theratechnologies on 7 of the 12 factors compared between the two stocks.
About Inozyme Pharma
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
About Theratechnologies
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
